Manager TitleAgeSince
Corporate Secretary 60 08/08/2019
Director TitleAgeSince
Director/Board Member 49 21/04/2020
Director/Board Member 60 07/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-0.81%-0.33%+27.15%+81.12% 5.52TCr
+2.17%-5.17%+28.33%+66.91% 5.38TCr
-0.11%+0.86%-15.63%-13.56% 2.35TCr
-1.58%-5.51%-3.51%+375.36% 2.2TCr
+2.49%-0.92%+20.31%-12.15% 1.98TCr
+0.09%-1.70%+28.45%-33.75% 1.74TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
+1.16%+0.58%+51.87%+181.96% 1.41TCr
-5.09%-10.87%+153.11%+272.20% 1.3TCr
Average -0.11%-1.55%+34.04%+162.05% 2.59TCr
Weighted average by Cap. +0.19%-0.44%+27.58%+125.14%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-